China Diagnostic Reagent Industry Report, 2013-2016
  • July 2014
  • Hard Copy
  • USD $2,550
  • Pages:140
  • Single User License
    (PDF Unprintable)       
  • USD $2,400
  • Code: ZLC-006
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,700
  • Hard Copy + Single User License
  • USD $2,750

With the accelerated aging of the Chinese population, the increase of personal health expenditure as well as the improved medical care facilities and government health care system, China diagnostic reagent industry has been developing quickly, especially in vitro diagnostic reagents occupy over 90%. In 2013, Chinese in vitro diagnostics market size reached RMB22.98 billion, of which RMB16.61 billion came from in vitro diagnostic reagents.

Chinese in vitro diagnostic reagent market consists of biochemical diagnostic reagents, immunodiagnostic reagents and molecular diagnostic reagents. Among them, the immune reagents and biochemical reagents account for a relatively higher combined proportion, such as around 65% in 2013.

Currently, about 40%-50% share of the Chinese in vitro diagnostics market has been dominated by foreign companies represented by Roche, Siemens, Abbott and Johnson & Johnson. Although there are 300-400 local enterprises in China in vitro diagnostics industry, the top ten Chinese companies which rank by production scale only seize 30% market share, reflecting a low industry concentration degree.

Mindray Medical, KHB, Fosun Pharmaceutical, Maker Biotechnology and Da An Gene act as giants in China in vitro diagnostics industry. Especially, Mindray Medical and KHB achieved the respective in vitro diagnostics revenue of RMB2.0458 billion and RMB1.0572 billion in 2013, accounting for 13.5% of the total jointly.

In 2014, a number of local Chinese diagnostic reagent companies (including BSBE, Maker Biotechnology, Health BioMed, Wondfo, Thalys) intend to step in the capital market through IPO because they are optimistic about the prospects of the diagnostic reagent industry; the raised funds will be used in the expansion of the existing projects or the construction of new projects. SHINVA, Humanwell Healthcare and Zhongyuan Union Stem Cell Bioengineering have entered the diagnostic reagent industry through acquisitions.

诊断试剂 英文_副本.png

The report covers the following:
20120114.gifStatus quo of China diagnostic reagent industry, including overview, market structure, import, export, competition pattern and so on;
20120114.gifDevelopment environments and trends of China diagnostic reagent industry, embracing macroeconomy, medical situation, and relevant policies;
20120114.gifOperation and diagnostic reagent business of 17 major companies in China diagnostic reagent industry.

1 Overview of Diagnostic Reagent Industry
1.1 Definition
1.2 Classification
1.3 Industry Chain

2 Status Quo of China Diagnostic Reagent Industry 
2.1 Overview 
2.2 Market Structure 
2.3 Import and Export 
2.3.1 Import 
2.3.2 Export 
2.4 Competition Pattern
2.5 Market Segments 
2.5.1 Biochemical Diagnostic Reagents
2.5.2 Immunodiagnostic Reagents
2.5.3 Molecular Diagnostic Reagents
2.5.4 Comprehensive In Vitro Diagnostic Reagents
3 Development Environments and Trends of China Diagnostic Reagent Industry 
3.1 Positive Factors 
3.1.1 Macroeconomy 
3.1.2 Medical Care
3.1.3 Policies 
3.2 Trends 
3.2.1 Biochemical Immunodiagnostics is still the Mainstream 
3.2.2 High Industrial Concentration Degree
3.2.3 Integrated Enterprises will See Better Development

4 Major Enterprises
4.1 Shanghai Kehua Bio-engineering Co., Ltd. (KHB) 
4.1.1 Profile
4.1.2 Operation 
4.1.3 Revenue Structure 
4.1.4 Gross Margin  
4.1.5 R & D and Investment  
4.1.6 Supply and Marketing
4.1.7 In Vitro Diagnostics Business 
4.1.8 Anticipation and Outlook 
4.2 Beijing Strong Biotechnologies, Inc (BSBE)
4.2.1 Profile
4.2.2 Operation 
4.2.3 Revenue Structure 
4.2.4 Gross Margin  
4.2.5 R & D and Investment  
4.2.6 Production and Marketing
4.2.7 Supply and Marketing
4.2.8 Anticipation and Outlook 
4.3 Da An Gene 
4.3.1 Profile
4.3.2 Operation 
4.3.3 Revenue Structure 
4.3.4 Gross Margin  
4.3.5 R & D and Investment  
4.3.6 Diagnostic Reagent Business 
4.3.7 Supply and Marketing
4.3.8 Anticipation and Outlook 
4.4 Fosun Pharmaceutical 
4.4.1 Profile
4.4.2 Operation 
4.4.3 Revenue Structure 
4.4.4 Gross Margin  
4.4.5 R & D and Investment  
4.4.6 Diagnostic Reagent Business 
4.4.7 Anticipation and Outlook 
4.5 Beijing Leadman Biochemistry Co., Ltd.
4.5.1 Profile
4.5.2 Operation 
4.5.3 Revenue Structure 
4.5.4 Gross Margin  
4.5.5 R & D and Investment  
4.5.6 Clients
4.5.7 Anticipation and Outlook 
4.6 Livzon Pharmaceutical Group Inc.
4.6.1 Profile
4.6.2 Operation 
4.6.3 Revenue Structure 
4.6.4 Gross Margin  
4.6.5 R & D 
4.6.6 Diagnostic Reagent Business
4.6.7 Anticipation and Outlook
4.7 Mindray Medical 
4.7.1 Profile
4.7.2 Operation 
4.7.3 Revenue Structure 
4.7.4 Gross Margin  
4.7.5 R & D and Investment  
4.7.6 Diagnostic Reagent Business 
4.7.7 Anticipation and Outlook 
4.8 Biosino Bio-Technology & Science Inc.
4.8.1 Profile
4.8.2 Operation 
4.8.3 Revenue Structure 
4.8.4 Gross Margin  
4.8.5 Anticipation and Outlook 
4.9 Maker Biotechnology 
4.9.1 Profile
4.9.2 Operation 
4.9.3 Revenue Structure 
4.9.4 Gross Margin  
4.9.5 R & D and Investment  
4.9.6 Supply and Marketing
4.9.7 Production and Marketing
4.9.8 Anticipation and Outlook 
4.10 Sinocare  
4.10.1 Profile
4.10.2 Operation 
4.10.3 Revenue Structure 
4.10.4 Gross Margin  
4.10.5 Anticipation and Outlook 
4.11 Beijing Kinghawk Pharmaceutical Co., Ltd.
4.11.1 Profile
4.11.2 Operation 
4.11.3 Revenue Structure 
4.11.4 Gross Margin  
4.11.5 Anticipation and Outlook 
4.12 Bohui Innovation 
4.12.1 Profile
4.12.2 Operation 
4.12.3 Revenue Structure 
4.12.4 Gross Margin  
4.12.5 R & D and Investment  
4.12.6 Anticipation and Outlook 
4.13 Health BioMed 
4.13.1 Profile
4.13.2 Operation 
4.13.3 Revenue Structure 
4.13.4 Gross Margin  
4.13.5 Supply and Marketing
4.13.6 R & D and Investment  
4.13.7 Anticipation and Outlook 
4.14 Wondfo 
4.14.1 Profile
4.14.2 Operation 
4.14.3 Revenue Structure 
4.14.4 Gross Margin  
4.14.5 Supply and Marketing
4.14.6 R & D and Investment  
4.14.7 Anticipation and Outlook 
4.15 Thalys
4.15.1 Profile
4.15.2 Operation 
4.15.3 Revenue Structure 
4.15.4 Gross Margin  
4.15.5 Production and Marketing
4.15.6 Supply and Marketing
4.15.7 R & D and Investment  
4.15.8 Anticipation and Outlook 
4.16 SHINVA 
4.16.1 Profile
4.16.2 Operation 
4.16.3 Gross Margin  
4.16.4 Diagnostic Reagent Business 
4.17 Humanwell Healthcare
4.17.1 Profile
4.17.2 Operation 
4.17.3 Diagnostic Reagent Business 

5 Summary and Forecast
5.1 Anticipation and Outlook of China Diagnostic Reagent Industry 
5.2 Operation Comparison between Major Companies
5.2.1 Revenue 
5.2.2 Net Income
5.2.3 Gross Margin  
5.2.4 In Vitro Diagnostics Business
Classification of In Vitro Diagnostic Reagents (by Detection Principle)
In Vitro Diagnostic Reagent Categories and Products (by National Policies)
Diagnostic Reagent Industry Chain
China’s In Vitro Diagnostics Market Size, 2009-2013
China’s In Vitro Diagnostic Reagent Market Structure, 2013
China’s Diagnostic Reagent Import Volume, 2008-2013
China’s Diagnostic Reagent Import Value, 2008-2013
China’s Diagnostic Reagent Import Sources and Value, 2012-2013
China’s Diagnostic Reagent Export Volume, 2008-2013
China’s Diagnostic Reagent Export Value, 2008-2013
Top 10 Destinations of Chinese Diagnostic Reagents by Export Volume and Value, 2012-2013
Diagnostic Instrument Comparison between Domestic and Foreign Enterprises 
Competition Pattern of China Diagnostic Reagent Industry  
In Vitro Diagnostics Revenue and Market Share of Major Diagnostic Reagent Companies in China, 2013
China’s GDP and YoY Growth Rate, 2004-2013
China’s Total Population and YoY Growth Rate, 2006-2013 
Population of 65-year-old People (or Older) and % of Total Population in China, 2004-2013
China's Health Expenditure and % of GDP, 1980-2013 
China's Per Capita Health Expenditure and YoY Growth Rate, 2006-2012 
Number of Medical Institutions In China, 2012-2013 
Workload of Health Institutions in China, 2012-2013
Main Policies of China Diagnostic Reagent Industry, 2010-2013
Development Process of Roche Diagnostics
Integrated Development Strategies of Global Leading Diagnostic Reagent Companies
KHB’s Revenue and Net Income, 2009-2013
KHB’s Revenue (by Product), 2009-2013
KHB’s Revenue Structure (by Product), 2009-2013
KHB’s Revenue (by Region), 2009-2013  
KHB’s Revenue Structure (by Region), 2009-2013  
KHB’s Gross Margin, 2009-2013
KHB’s Gross Margin (by Product), 2009-2013
KHB’s Gross Margin (by Region), 2010-2013  
KHB’s R & D Costs and % of Total Revenue, 2011-2013
Key National Projects Involved with KHB 
KHB’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
Comparison between KHB’s Top 5 Clinets, 2012-2013
Comparison between KHB’s Top 5 Suppliers, 2012-2013
KHB’s Medical Instrument Categories and Products, 2013
KHB’s Revenue and Net Income, 2012-2016E
BSBE’s Revenue and Net Income, 2011-2013
BSBE’s Revenue and Structure (by Product), 2011-2013
BSBE’s Gross Margin, 2011-2013
Gross Margin of BSBE’s Independent Products, 2011-2013
Gross Margin of BSBE’s Agent Products, 2011-2013
BSBE’s R & D Costs and % of Total Revenue, 2011-2013
BSBE’s Investment Projects and Value  
BSBE’s Capacity, Output and Sales Volume, 2011-2013
BSBE’s Top 10 Products by Sales, 2013
BSBE’s Top 5 Raw Material Suppliers, 2011-2013
BSBE’s Top 5 Distributors, 2011-2013
BSBE’s Revenue and Net Income, 2011-2016E 
Revenue and Net Income of Da An Gene, 2009-2013
Revenue of Da An Gene (by Product) , 2009-2013
Revenue Structure of Da An Gene (by Product) , 2009-2013
Revenue of Da An Gene (by Region), 2009-2013  
Revenue Structure of Da An Gene (by Product) , 2009-2013
Gross Margin of Da An Gene, 2009-2013  
Gross Margin of Da An Gene (by Product), 2009-2013  
R & D Costs and % of Total Revenue of Da An Gene, 2011-2013
Reagent Revenue and YoY Growth of Da An Gene, 2009-2013 
Instrument Revenue and YoY Growth Rate of Da An Gene, 2009-2013 
Principal Assets and Business of Da An Gene 
Medical Resources of Sun Yat-sen University
Top 5 Clients of Da An Gene, 2013 
Top 5 Clients of Da An Gene, 2012 
Top 5 Suppliers of Da An Gene, 2013 
Top 5 Suppliers of Da An Gene, 2012 
Revenue and Net Income of Da An Gene, 2012-2016E 
Revenue and Net Income of Fosun Pharmaceutical, 2009-2013
Revenue of Fosun Pharmaceutical (by Business), 2009-2013  
Revenue Structure of Fosun Pharmaceutical (by Business), 2009-2013  
Revenue of Fosun Pharmaceutical (by Region), 2009-2013  
Revenue Structure of Fosun Pharmaceutical (by Region), 2009-2013  
Gross Margin of Fosun Pharmaceutical, 2009-2013
Gross Margin of Fosun Pharmaceutical (by Business), 2009-2013  
R & D Costs and % of Total Revenue of Fosun Pharmaceutical, 2010-2013
Medical Diagnosis and Medical Equipment Revenue as well as % of Total Revenue of Fosun Pharmaceutical, 2009-2013
Revenue and Net Income of Fosun Pharmaceutical, 2012-2016E 
Leadman's Revenue and Net Income, 2009-2013 
Leadman's Revenue (by Product), 2009-2013 
Leadman's Revenue Structure (by Product), 2009-2013 
Leadman's Gross Margin, 2009-2013 
Leadman's Gross Margin (by Product), 2009-2013 
Leadman's R & D Costs and% of Total Revenue, 2011-2013 
Leadman's Top 5 Clients, 2013 
Leadman's Top 5 Clients, 2012 
Leadman's Revenue and Net Income, 2012-2016E 
Livzon’s Revenue and Net Income, 2009-2013
Livzon’s Revenue (by Product), 2009-2013
Livzon’s Revenue Structure (by Product), 2009-2013
Livzon’s Revenue (by Region), 2009-2013  
Livzon’s Revenue Structure (by Region), 2009-2013  
Livzon’s Gross Margin, 2009-2013
Livzon’s Gross Margin (by Product), 2009-2013
Livzon’s Main Diagnostic Reagent Products
Revenue and YoY Growth Rate of Livzon’s Diagnostic Reagents and Equipment, 2009-2013
Livzon’s Revenue and Net Income, 2012-2016E 
Revenue and Net Income of Mindray Medical, 2009-2013
Revenue of Mindray Medical (by Product), 2009-2013
Revenue Structure of Mindray Medical (by Product), 2009-2013
Gross Margin of Mindray Medical, 2009-2013 
R & D Costs and % of Total Revenue of Mindray Medical, 2009-2013
In Vitro Diagnostic Product Revenue and YoY Growth Rate of Mindray Medical, 2009-2013
Revenue and Net Income of Mindray Medical, 2012-2016E 
Biosino’s Revenue and Net Income, 2009-2013
Biosino’s Revenue (by Product), 2009-2013
Biosino’s Revenue Structure (by Product), 2009-2013
Biosino’s Gross Margin, 2009-2013
Biosino’s Revenue and Net Income, 2012-2016E 
Product Structure of Maker Biotechnology 
Revenue and Net Income of Maker Biotechnology, 2011-2013
Sales and Structure of Independent Products of Maker Biotechnology, 2011-2013
Agent Brand Sales and Structure of Maker Biotechnology, 2011-2013
Sales and Structure of Maker Biotechnology (by Client), 2011-2013
Comparison between Direct sales and Distribution Revenue of Maker Biotechnology (by Region), 2011-2013   
Gross Margin of Maker Biotechnology, 2011-2013 
R & D Costs and % of Total Revenue of Maker Biotechnology, 2011-2013
Investment Projects and Value of Maker Biotechnology
Top 10 Suppliers of Maker Biotechnology, 2012-2013
Dealer Distribution of Maker Biotechnology, 2011-2013
Top 5 Clients of Maker Biotechnology, 2011-2013
Capacity, Output and Sales Volume of Maker Biotechnology, 2011-2013 
Comparison between Independent Diagnostic Products and Agent Diagnostic Products of Maker Biotechnology
Revenue and Net Income of Maker Biotechnology, 2012-2016E 
Sinocare’s Revenue and Net Income, 2009-2013
Sinocare’s Revenue Structure (by Product), 2009-2013
Sinocare’s Gross Margin, 2009-2013   
Sinocare’s Gross Margin (by Product), 2009-2013  
Sinocare’s Revenue and Net Income, 2012-2016E 
Revenue and Net Income of Kinghawk Pharmaceutical, 2009-2013 
Revenue of Kinghawk Pharmaceutical (by Product), 2010-2012  
Revenue Structure of Kinghawk Pharmaceutical (by Product), 2010-2012  
Gross Margin of Kinghawk Pharmaceutical, 2009-2013
Gross Margin of Kinghawk Pharmaceutical (by Product), 2010-2012 
Revenue and Net Income of Kinghawk Pharmaceutical, 2012-2016E 
Revenue and Net Income of Bohui Innovation, 2009-2013
Revenue of Bohui Innovation (by Product), 2009-2013
Revenue Structure of Bohui Innovation (by Product), 2009-2013
Gross Margin of Bohui Innovation, 2009-2013
Gross Margin of Bohui Innovation (by Product), 2009-2013
R & D Costs and % of Total Revenue of Bohui Innovation, 2010-2013
Revenue and Net Income of Bohui Innovation, 2012-2016E 
Revenue and Net Income of Health BioMed, 2011-2013
Revenue and Structure of Health BioMed (by Product), 2011-2013 
Revenue and Structure of Health BioMed (by Region), 2011-2013 
Revenue and Structure of Health BioMed (by Client), 2011-2013 
Gross Margin of Health BioMed, 2011-2013  
Gross Margin of Health BioMed (by Product), 2011-2013
Top 5 Suppliers of Health BioMed, 2011-2013  
Top 5 Clients of Health BioMed, 2011-2013 
R & D Costs and % of Total Revenue of Health BioMed, 2011-2013
In Vitro Diagnostic Items, Product Categories and Operation Modes of Health BioMed
Investment Projects and Value of Health BioMed  
Revenue and Net Income of Health BioMed, 2011-2016E 
Application and Detection Methods of Wondfo's Products
Wondfo’s Revenue and Net Income, 2011-2013
Wondfo’s Revenue (by Product), 2011-2013
Wondfo’s Revenue Structure (by Product), 2011-2013
Wondfo’s Revenue (by Region), 2011-2013  
Wondfo’s Gross Margin, 2011-2013  
Wondfo’s Gross Margin (by Product), 2011-2013 
Wondfo’s Top 5 Suppliers, 2011-2013  
Wondfo’s Top 5 Clients, 2011-2013  
Wondfo’s R & D Costs and % of Total Revenue, 2011-2013
Wondfo’s Investment Projects and Purposes of Raised Funds
Wondfo’s Revenue and Net Income, 2011-2016E 
Revenue and Net Income of Thalys, 2011-2013
Revenue and Structure of Thalys (by Business), 2011-2013   
Revenue and Structure of Thalys (by Region), 2011-2013   
Gross Margin of Thalys, 2011-2013 
Gross Margin of Thalys (by Business), 2011-2013  
Capacity, Output, Sales Volume, Capacity Utilization and Sales/Output Ratio of Thalys’ Independent Products, 2011-2013
Top 5 Clients of Thalys, 2011-2013 
Top 5 Suppliers of Thalys, 2011-2013  
Sales and R & D COSTS of Thalys’ Independent Products, 2011-2013
Investment Projects and Raised Funds of Thalys
Revenue and Net Income of Thalys, 2011-2016E 
SHINVA’s Revenue and Net Income, 2009-2013
SHINVA’s Gross Margin, 2009-2013   
Revenue and Net Income of Humanwell Healthcare, 2009-2013 
Chinese In Vitro Diagnostics Market Size, 2012-2016E
Revenue Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013
Net Income Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013
Net Profit Margin Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013
Gross Margin Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013
In Vitro Diagnostics Revenue Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013

China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号